Biodesix Inc (BDSX)vsJohnson & Johnson (JNJ)
BDSX
Biodesix Inc
$17.35
-6.30%
HEALTHCARE · Cap: $161.55M
JNJ
Johnson & Johnson
$232.77
+1.27%
HEALTHCARE · Cap: $567.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 100177% more annual revenue ($96.36B vs $96.10M). JNJ leads profitability with a 21.8% profit margin vs -33.3%. JNJ earns a higher WallStSmart Score of 57/100 (C).
BDSX
Avoid31
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.0%
Fair Value
$8.70
Current Price
$17.35
$8.65 premium
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$232.77
$96.65 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.3% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Trading at 19.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -349.9% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : BDSX
The primary concerns for BDSX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.84 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
BDSX carries more volatility with a beta of 0.59 — expect wider price swings.
BDSX is growing revenue faster at 42.3% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 31/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?